Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • CA-125 Antigen
  • Fallopian Tube Neoplasms
  • Ovarian Neoplasms
  • Peritoneal Neoplasms

abstract

  • Immunization with abagovomab is well tolerated and induced robust Ab3 responses at the two doses and routes tested. A phase III randomized study with abagovomab (2.0 mg s.c.) is warranted.

publication date

  • September 15, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-05-2670

PubMed ID

  • 17000686

Additional Document Info

start page

  • 5503

end page

  • 10

volume

  • 12

number

  • 18